310 related articles for article (PubMed ID: 16039041)
1. Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers.
Chuang SC; Hashibe M; Yu GP; Le AD; Cao W; Hurwitz EL; Rao JY; Neugut AI; Zhang ZF
Cancer Lett; 2006 Jul; 238(1):42-52. PubMed ID: 16039041
[TBL] [Abstract][Full Text] [Related]
2. Risk of Second Primary Malignancies After External Beam Radiotherapy for Thyroid Cancer.
Jin MC; Qian ZJ; Megwalu UC
Anticancer Res; 2022 Mar; 42(3):1359-1365. PubMed ID: 35220228
[TBL] [Abstract][Full Text] [Related]
3. Radiation treatment of patients with primary pediatric malignancies: risk of developing thyroid cancer as a secondary malignancy.
Rose J; Wertheim BC; Guerrero MA
Am J Surg; 2012 Dec; 204(6):881-6; discussion 886-7. PubMed ID: 23026382
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy for oral cancer as a risk factor for second primary cancers.
Hashibe M; Ritz B; Le AD; Li G; Sankaranarayanan R; Zhang ZF
Cancer Lett; 2005 Apr; 220(2):185-95. PubMed ID: 15766594
[TBL] [Abstract][Full Text] [Related]
5. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk.
Chaturvedi AK; Engels EA; Gilbert ES; Chen BE; Storm H; Lynch CF; Hall P; Langmark F; Pukkala E; Kaijser M; Andersson M; Fosså SD; Joensuu H; Boice JD; Kleinerman RA; Travis LB
J Natl Cancer Inst; 2007 Nov; 99(21):1634-43. PubMed ID: 17971527
[TBL] [Abstract][Full Text] [Related]
6. Cancer incidence after localized therapy for prostate cancer.
Moon K; Stukenborg GJ; Keim J; Theodorescu D
Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
[TBL] [Abstract][Full Text] [Related]
7. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.
Brown AP; Chen J; Hitchcock YJ; Szabo A; Shrieve DC; Tward JD
J Clin Endocrinol Metab; 2008 Feb; 93(2):504-15. PubMed ID: 18029468
[TBL] [Abstract][Full Text] [Related]
8. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries.
Berrington de Gonzalez A; Curtis RE; Kry SF; Gilbert E; Lamart S; Berg CD; Stovall M; Ron E
Lancet Oncol; 2011 Apr; 12(4):353-60. PubMed ID: 21454129
[TBL] [Abstract][Full Text] [Related]
9. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
10. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.
Berrington de Gonzalez A; Wong J; Kleinerman R; Kim C; Morton L; Bekelman JE
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):295-302. PubMed ID: 25636756
[TBL] [Abstract][Full Text] [Related]
11. Radiation and Second Primary Thyroid Cancer Following Index Head and Neck Cancer.
Polednik KM; Simpson MC; Adjei Boakye E; Mohammed KA; J Dombrowski J; Varvares MA; Osazuwa-Peters N
Laryngoscope; 2019 Apr; 129(4):1014-1020. PubMed ID: 30208210
[TBL] [Abstract][Full Text] [Related]
12. A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations.
Brown AP; Neeley ES; Werner T; Soisson AP; Burt RW; Gaffney DK
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):127-35. PubMed ID: 19910129
[TBL] [Abstract][Full Text] [Related]
13. Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study.
Taylor AJ; Croft AP; Palace AM; Winter DL; Reulen RC; Stiller CA; Stevens MC; Hawkins MM
Int J Cancer; 2009 Nov; 125(10):2400-5. PubMed ID: 19610069
[TBL] [Abstract][Full Text] [Related]
14. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
15. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study.
Teng CJ; Hu YW; Chen SC; Yeh CM; Chiang HL; Chen TJ; Liu CJ
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26538627
[TBL] [Abstract][Full Text] [Related]
16. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
Sawka AM; Thabane L; Parlea L; Ibrahim-Zada I; Tsang RW; Brierley JD; Straus S; Ezzat S; Goldstein DP
Thyroid; 2009 May; 19(5):451-7. PubMed ID: 19281429
[TBL] [Abstract][Full Text] [Related]
17. Risk of mesothelioma following external beam radiotherapy for prostate cancer: a cohort analysis of SEER database.
Farioli A; Violante FS; Mattioli S; Curti S; Kriebel D
Cancer Causes Control; 2013 Aug; 24(8):1535-45. PubMed ID: 23702885
[TBL] [Abstract][Full Text] [Related]
18. Association of colorectal cancer and prostate cancer and impact of radiation therapy.
Huo D; Hetzel JT; Roy H; Rubin DT
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1979-85. PubMed ID: 19531678
[TBL] [Abstract][Full Text] [Related]
19. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma.
Bhattacharyya N; Chien W
Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):607-10. PubMed ID: 16944659
[TBL] [Abstract][Full Text] [Related]
20. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database.
Farioli A; Ottone M; Morganti AG; Compagnone G; Romani F; Cammelli S; Mattioli S; Violante FS
Cancer Med; 2016 May; 5(5):950-9. PubMed ID: 26860323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
